ArticleFrontiers in oncology2022
Nanozyme Hydrogels for Self-Augmented Sonodynamic/Photothermal Combination Therapy.
Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 27 citations in OpenAlex.
- Emerging versatile nanozymes for the therapeutic and diagnostic applications of diseases.Journal of translational medicine · 2025Review
- Nanosensitizer-assisted sonodynamic therapy for breast cancer.Journal of nanobiotechnology · 2025Review
- Multidimensional insights into exosomes in hepatocellular carcinoma: from genesis to clinical application.Frontiers in immunology · 2025Review
- Advancing cancer treatment with nanozyme frameworks: Integrating photothermal, photodynamic, sonodynamic, and chemodynamic therapies.Iranian journal of basic medical sciences · 2025Review
- Removing Barriers to Tumor 'Oxygenation': Depleting Glutathione Nanozymes in Cancer Therapy.International journal of nanomedicine · 2025Review
- The recent research progress in the application of the nanozyme-hydrogel composite system for drug delivery.Drug delivery · 2024Review
- Nanotechnology-enabled sonodynamic therapy against malignant tumors.Nanoscale advances · 2024Review
- Neuromodulation by nanozymes and ultrasound during Alzheimer's disease management.Journal of nanobiotechnology · 2024Review
- Magnetically actuated sonodynamic nanorobot collectives for potentiated ovarian cancer therapy.Frontiers in bioengineering and biotechnology · 2024Article
- Cu-doped polypyrrole hydrogel with tumor catalyst activity for NIR-II thermo-radiotherapy.Frontiers in bioengineering and biotechnology · 2023Article
- The multifunctional Prussian blue/graphitic carbon nitride nanocomposites for fluorescence imaging-guided photothermal and photodynamic combination therapy.RSC advances · 2022Article
- A novel dual MoSFrontiers in bioengineering and biotechnology · 2022Article
- Colon cancer exosome-derived biomimetic nanoplatform for curcumin-mediated sonodynamic therapy and calcium overload.Frontiers in bioengineering and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sonosensitizer-mediated sonodynamic therapy (SDT) has emerged as a promising anti-tumor strategy. However, this strategy of continuous oxygen consumption further exacerbates the hypoxic tumor microenvironment, which limits its therapeutic efficacy. In this study, we designed a multifunctional hydrogel (PB+Ce6@Hy) that simultaneously co-delivers nanozyme prussian blue (PB) and sonosensitizer chlorin e6 (Ce6) for the realization of photothermal therapy (PTT) and enhanced SDT. When the hydrogel reaches the tumor tissue through local injection, the 808 nm laser can induce the hydrogel to warm up and soften, thereby triggering the release of PB and Ce6. PB can interact with endogenous H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.